MA44018B1 - Dérivés de tétrahydroisoquinoline - Google Patents
Dérivés de tétrahydroisoquinolineInfo
- Publication number
- MA44018B1 MA44018B1 MA44018A MA44018A MA44018B1 MA 44018 B1 MA44018 B1 MA 44018B1 MA 44018 A MA44018 A MA 44018A MA 44018 A MA44018 A MA 44018A MA 44018 B1 MA44018 B1 MA 44018B1
- Authority
- MA
- Morocco
- Prior art keywords
- muscle
- troponin
- disorders
- tetrahydroisoquinoline
- treating
- Prior art date
Links
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 abstract 4
- 102000004903 Troponin Human genes 0.000 abstract 4
- 108090001027 Troponin Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000002235 sarcomere Anatomy 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 206010049565 Muscle fatigue Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 208000016334 muscle symptom Diseases 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 210000003903 pelvic floor Anatomy 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 210000005070 sphincter Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne de nouveaux composés dérivés de la tétrahydroisoquinoline qui peuvent être utilisés à titre de principe actif pour une composition pharmaceutique, et en particulier, pour une composition pharmaceutique utile pour prévenir ou traiter une maladie ou une affection sensible à la modulation de la contractilité du sarcomère squelettique. L'objectif est atteint, par exemple, par modulation du complexe de troponine du sarcomère du muscle squelettique rapide par l'intermédiaire d'un ou de plusieurs des filaments suivants : myosine squelettique rapide, actine, tropomyosine, troponine c, troponine i et troponine t, leurs fragments et isoformes. Les composés dérivés de la tétrahydroisoquinoline peuvent ainsi être utilisés comme agent pour prévenir ou traiter 1) les troubles neuromusculaires, 2) les troubles du muscle volontaire, 3) les troubles du snc dans lesquels la faiblesse, l'atrophie, et la fatigue musculaires sont des symptômes importants, 4) les symptômes musculaires provenant de troubles systémiques, et 5) les dysfonctions du plancher pelvien et du muscle sphincter urétral/anal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662285039P | 2016-02-12 | 2016-02-12 | |
| PCT/US2017/017295 WO2017139526A1 (fr) | 2016-02-12 | 2017-02-10 | Dérivés de tétrahydroisoquinoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44018A MA44018A (fr) | 2018-12-19 |
| MA44018B1 true MA44018B1 (fr) | 2022-05-31 |
Family
ID=59561239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44018A MA44018B1 (fr) | 2016-02-12 | 2017-02-10 | Dérivés de tétrahydroisoquinoline |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9914741B2 (fr) |
| EP (2) | EP4032877A1 (fr) |
| JP (2) | JP6832943B2 (fr) |
| KR (1) | KR20180120701A (fr) |
| CN (2) | CN113666938A (fr) |
| AR (1) | AR107592A1 (fr) |
| AU (1) | AU2017217663B2 (fr) |
| BR (1) | BR112018016475A2 (fr) |
| CA (1) | CA3012839A1 (fr) |
| CL (1) | CL2018002287A1 (fr) |
| CO (1) | CO2018007920A2 (fr) |
| CY (1) | CY1125222T1 (fr) |
| DK (1) | DK3413892T3 (fr) |
| ES (1) | ES2913423T3 (fr) |
| HR (1) | HRP20220655T1 (fr) |
| HU (1) | HUE058820T2 (fr) |
| IL (1) | IL261055B (fr) |
| LT (1) | LT3413892T (fr) |
| MA (1) | MA44018B1 (fr) |
| MD (1) | MD3413892T2 (fr) |
| MX (1) | MX379159B (fr) |
| NZ (1) | NZ746311A (fr) |
| PH (1) | PH12018501694B1 (fr) |
| PL (1) | PL3413892T3 (fr) |
| PT (1) | PT3413892T (fr) |
| RS (1) | RS63240B1 (fr) |
| RU (1) | RU2743424C2 (fr) |
| SG (1) | SG11201806416XA (fr) |
| SI (1) | SI3413892T1 (fr) |
| SM (1) | SMT202200201T1 (fr) |
| TW (2) | TWI719138B (fr) |
| UA (1) | UA124879C2 (fr) |
| WO (1) | WO2017139526A1 (fr) |
| ZA (1) | ZA201804947B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200201T1 (it) | 2016-02-12 | 2022-07-21 | Cytokinetics Inc | Derivati di tetraidroisochinolina |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| JP7825618B2 (ja) * | 2020-11-06 | 2026-03-06 | サイトキネティックス， インコーポレイテッド | 二環式１，４－ジアゼパノン及びその治療的使用 |
| WO2025080100A1 (fr) * | 2023-10-11 | 2025-04-17 | 한국화학연구원 | Nouveau composé di-amide, son procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer ou de maladies auto-immunes le comprenant en tant que principe actif |
| CN117379425A (zh) * | 2023-11-14 | 2024-01-12 | 广州日聚商贸发展有限公司 | 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3301857A (en) | 1963-08-26 | 1967-01-31 | Hoffmann La Roche | Spiro |
| SE368009B (fr) | 1971-09-16 | 1974-06-17 | Kabi Ab | |
| EA003188B1 (ru) * | 1996-08-06 | 2003-02-27 | Пфайзер Инк | Замещенные пиридо- или пиримидосодержащие 6,6- или 6,7-бициклические производные |
| WO1998013350A1 (fr) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Derives quinolines inhibant les effets de facteurs de croissance tels que le facteur de croissance endotheliale vasculaire |
| US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US6743599B1 (en) | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US7202051B1 (en) | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| US6958333B1 (en) * | 1999-07-26 | 2005-10-25 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| ZA200609261B (en) * | 2004-04-28 | 2008-08-27 | Takeda Pharmaceutical | Fused quinoline derivative and use thereof |
| BRPI0620151A2 (pt) * | 2005-12-22 | 2010-06-29 | Wyeth Corp | composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| EP2666777A1 (fr) * | 2006-08-02 | 2013-11-27 | Cytokinetics, Inc. | Certaines entités chimiques avec un noyeau imidazo<4,5-b>pyrazin-2(3H)-one, compositions et procédés |
| JP5405314B2 (ja) | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノロン誘導体 |
| PL2097400T3 (pl) | 2007-01-05 | 2013-11-29 | Daiichi Sankyo Co Ltd | Skondensowane podstawione pochodne aminopirolidyny |
| WO2008147547A1 (fr) | 2007-05-25 | 2008-12-04 | Amgen Inc. | Composés d'hydroxyéthylamine substitués en tant que modulateurs de la bêta-sécrétase et procédés d'utilisation |
| US8383629B2 (en) * | 2008-02-27 | 2013-02-26 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
| CN101518971B (zh) * | 2008-02-29 | 2012-07-18 | E.I.内穆尔杜邦公司 | 聚酯叠层膜和使用该叠层膜的太阳能电池板 |
| PL2344471T3 (pl) * | 2008-10-02 | 2013-12-31 | Taisho Pharmaceutical Co Ltd | Pochodna 7-piperydynoalkilo-3,4-dihydrochinolonu |
| EP2365752B1 (fr) | 2008-10-29 | 2014-09-24 | Deciphera Pharmaceuticals, Llc | Amides de cyclopropane et analogues présentant des activités anticancéreuses et antiprolifératives |
| WO2010131145A1 (fr) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Dérivés de cyclobutène-dione |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2011133920A1 (fr) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation |
| JP5860042B2 (ja) | 2010-06-16 | 2016-02-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用 |
| KR20140009372A (ko) * | 2011-02-18 | 2014-01-22 | 알러간, 인코포레이티드 | 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| HUP1100241A3 (en) * | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
| AU2013243671B2 (en) | 2012-04-02 | 2017-09-21 | Cytokinetics, Inc. | Methods for improving diaphragm function |
| CN104395458A (zh) | 2012-04-11 | 2015-03-04 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力 |
| AR091699A1 (es) * | 2012-07-10 | 2015-02-25 | Astellas Pharma Inc | Derivado de indol carboxamida |
| EP3137622B1 (fr) | 2014-04-29 | 2021-11-24 | Cytokinetics, Inc. | Méthodes de réduction du déclin de la capacité vitale |
| ES2750751T3 (es) | 2014-09-09 | 2020-03-27 | Astellas Pharma Inc | Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria |
| SMT202200201T1 (it) | 2016-02-12 | 2022-07-21 | Cytokinetics Inc | Derivati di tetraidroisochinolina |
-
2017
- 2017-02-10 SM SM20220201T patent/SMT202200201T1/it unknown
- 2017-02-10 AR ARP170100336A patent/AR107592A1/es unknown
- 2017-02-10 KR KR1020187026486A patent/KR20180120701A/ko not_active Withdrawn
- 2017-02-10 EP EP22160176.8A patent/EP4032877A1/fr not_active Withdrawn
- 2017-02-10 CA CA3012839A patent/CA3012839A1/fr active Pending
- 2017-02-10 AU AU2017217663A patent/AU2017217663B2/en not_active Ceased
- 2017-02-10 PL PL17750801T patent/PL3413892T3/pl unknown
- 2017-02-10 ES ES17750801T patent/ES2913423T3/es active Active
- 2017-02-10 NZ NZ746311A patent/NZ746311A/en not_active IP Right Cessation
- 2017-02-10 EP EP17750801.7A patent/EP3413892B1/fr active Active
- 2017-02-10 HR HRP20220655TT patent/HRP20220655T1/hr unknown
- 2017-02-10 MD MDE20181214T patent/MD3413892T2/ro unknown
- 2017-02-10 MX MX2018009759A patent/MX379159B/es unknown
- 2017-02-10 DK DK17750801.7T patent/DK3413892T3/da active
- 2017-02-10 SI SI201731142T patent/SI3413892T1/sl unknown
- 2017-02-10 CN CN202110837700.6A patent/CN113666938A/zh active Pending
- 2017-02-10 SG SG11201806416XA patent/SG11201806416XA/en unknown
- 2017-02-10 RS RS20220483A patent/RS63240B1/sr unknown
- 2017-02-10 PT PT177508017T patent/PT3413892T/pt unknown
- 2017-02-10 US US15/429,738 patent/US9914741B2/en active Active
- 2017-02-10 BR BR112018016475-5A patent/BR112018016475A2/en active Search and Examination
- 2017-02-10 UA UAA201809258A patent/UA124879C2/uk unknown
- 2017-02-10 TW TW106104493A patent/TWI719138B/zh not_active IP Right Cessation
- 2017-02-10 RU RU2018130002A patent/RU2743424C2/ru active
- 2017-02-10 WO PCT/US2017/017295 patent/WO2017139526A1/fr not_active Ceased
- 2017-02-10 LT LTEPPCT/US2017/017295T patent/LT3413892T/lt unknown
- 2017-02-10 PH PH1/2018/501694A patent/PH12018501694B1/en unknown
- 2017-02-10 MA MA44018A patent/MA44018B1/fr unknown
- 2017-02-10 CN CN201780010949.1A patent/CN109069498B/zh not_active Expired - Fee Related
- 2017-02-10 HU HUE17750801A patent/HUE058820T2/hu unknown
- 2017-02-10 TW TW110103986A patent/TWI773118B/zh not_active IP Right Cessation
- 2017-02-10 JP JP2018541693A patent/JP6832943B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-17 US US15/873,571 patent/US10259821B2/en active Active
- 2018-07-23 ZA ZA2018/04947A patent/ZA201804947B/en unknown
- 2018-07-30 CO CONC2018/0007920A patent/CO2018007920A2/es unknown
- 2018-08-08 IL IL261055A patent/IL261055B/en active IP Right Grant
- 2018-08-10 CL CL2018002287A patent/CL2018002287A1/es unknown
-
2019
- 2019-03-04 US US16/291,481 patent/US10689393B2/en active Active
-
2020
- 2020-05-11 US US16/871,532 patent/US11479561B2/en active Active
-
2021
- 2021-02-01 JP JP2021014223A patent/JP7137650B2/ja active Active
-
2022
- 2022-06-03 CY CY20221100392T patent/CY1125222T1/el unknown
- 2022-09-13 US US17/944,060 patent/US20230125280A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44018B1 (fr) | Dérivés de tétrahydroisoquinoline | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA42456A (fr) | Inhibiteurs de hpk1 et leurs procédés d'utilisation | |
| EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| PE20220425A1 (es) | Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| BR0008687A (pt) | Métodos para o tratamento de, e para prevenir ou controlar, distúrbios gastrointestinais, disfunção da motilidade gastrointestinal, emese, e doença de refluxo gastro-esofageano em um paciente, e, composição farmacêutica | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| GEAP202516611A (en) | Nlrp3 modulators | |
| MA30296B1 (fr) | Nouvelles amines | |
| MA30313B1 (fr) | Amines secondaires en tant qu'inhibiteurs de la renine | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| MA29439B1 (fr) | Derives d'uree d'heteroaryle utilises pour inhiber chk1 | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA29723B1 (fr) | Composes | |
| MA45803A1 (fr) | Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage | |
| Kumar et al. | Esomeprazole reduces sperm motility index by targeting the spermic cholinergic machinery: A mechanistic study for the association between use of proton pump inhibitors and reduced sperm motility index | |
| Faturi et al. | Intermittent stretching induces fibrosis in denervated rat muscle |